A 5-year Longitudinal Observational Study of Patients Undergoing

Therapy for IMISC (TARGET-DERM)

ID# NCT03661866

Recruitment Status: Recruiting

Estimated Study Completion Date: December 31, 2026

HS Connect listed this: October 2020

 

Sponsor: Target PharmaSolutions, Inc.

Information provided by (Responsible Party): Target PharmaSolutions, Inc.

 

Brief Summary:

 

TARGET-DERM is a 5-year, longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.

 

Please link for complete trial details:

 

https://clinicaltrials.gov/ct2/show/NCT03661866

 

Location:

 

Multiple US locations. Please see link provided above for all location details and to confirm your location is recruiting.

 

Contact Information: 

 

Contact: Laura Dalfonso Phone: 9842340268

Email: ldalfonso@targetpharmasolutions.com

 

Laura Malahias Phone: 9842340268 ext 209

Email: lmalahias@targetpharmasolutions.com

Get Updates

Affiliated With

© 2020 by HS Connect   |  HSConnect.org@gmail.com  |  PO Box 73244 Puyallup, WA 98373  |  253.256.1579